Adalimumab biosimilar(Protheragen)

N/A

Report date: 2025/03/07 17:34:21

Base Information

Drug NameAdalimumab biosimilar(Protheragen)
Drug Alias NameProS-01
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionImmunosuppressantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsCrohn DiseaseArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesProtheragen Inc
China Registration ClassN/A

Develop Information

Active CompaniesProtheragen Inc
Inactive CompaniesN/A
Active IndicationsCrohn DiseaseArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A